{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:06:14Z","timestamp":1765609574667},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Zoledronic acid is a potent inhibitor of osteoclast-mediated bone resorption and has been widely used in bone metastasis malignancies and postmenopausal osteoporosis as a preventive therapy against skeletal-related events. The purpose of this study was to evaluate the clinical outcome of zoledronic acid as an adjuvant therapy for patients with early stage breast cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and methods<\/jats:title>\n            <jats:p>Entries in the PubMed and EMBASE databases up to 12 July 2013 were systematically reviewed. Online abstracts from the proceedings of the Annual Meetings of the American Society of Clinical Oncology (ASCO) (1992\u20132013) and the San Antonio Breast Cancer Symposium (SABCS) (2004\u20132013) were also reviewed. Primary endpoints included overall survival (OS) and disease-free survival (DFS), while secondary endpoints included bone metastasis-free survival (BMFS), distant metastasis-free survival (DMFS), and fracture-free rate (FFR).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of eight studies including 3,866 subjects and 3,864 controls met our search criteria and were evaluated. The use of zoledronic acid was found to improve OS (relative risk (RR), 0.88; 95% confidence interval (CI), 0.77\u20131.01; <jats:italic>p-<\/jats:italic> value\u2009=\u20090.06) and DMFS (RR, 0.77; 95% CI, 0.60\u20131.00; <jats:italic>p-<\/jats:italic> value\u2009=\u20090.05). Furthermore, statistically significant benefits were associated with BMFS (RR, 0.81; 95% CI, 0.66\u20130.99; <jats:italic>p-<\/jats:italic> value\u2009=\u20090.04) and FFRs (RR, 0.75; 95% CI, 0.61\u20130.92; <jats:italic>p-<\/jats:italic> value\u2009=\u20090.007). In contrast, there was no significant difference in DFS with the application of zoledronic acid (RR, 0.88; 95% CI, 0.72\u20131.09; <jats:italic>p-<\/jats:italic> value\u2009=\u20090.24). Sensitivity analysis further identified the improvement of 5-year OS for the adjuvant zoledronic acid therapy in early stage breast cancer patients (RR, 0.86; 95% CI, 0.75\u20130.99; <jats:italic>p-<\/jats:italic> value\u2009=\u20090.03), while a borderline statistically significant benefit was observed for 5-year DFS (RR, 0.90; 95% CI, 0.81\u20131.00; <jats:italic>p-<\/jats:italic> value\u2009=\u20090.06).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Zoledronic acid as an adjuvant therapy appears to improve the 5-year OS rate for early stage breast cancer patients, and was associated with a protective effect for the bone metastases and fractures evaluated in more than 7,000 patients. However, further research is needed to confirm our findings, and sub-group analyses according to menopause status or hormone status may provide further insight.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1756-8722-6-80","type":"journal-article","created":{"date-parts":[[2013,10,23]],"date-time":"2013-10-23T11:17:51Z","timestamp":1382527071000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis"],"prefix":"10.1186","volume":"6","author":[{"given":"Mingfeng","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weidong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianquan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,23]]},"reference":[{"key":"357_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.20138","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 2012, 62: 10-29. 10.3322\/caac.20138.","journal-title":"CA Cancer J Clin"},{"key":"357_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/bjc.1987.13","volume":"55","author":"RE Coleman","year":"1987","unstructured":"Coleman RE, Rubens RD: The clinical course of bone metastases from breast cancer. Br J Cancer. 1987, 55: 61-66. 10.1038\/bjc.1987.13.","journal-title":"Br J Cancer"},{"key":"357_CR3","first-page":"97","volume":"5","author":"ML Svendsen","year":"2013","unstructured":"Svendsen ML, Gammelager H, Sv\u00e6rke C, Yong M, Chia VM, Christiansen CF, Fryzek JP: Hospital visits among women with skeletal-related events secondary to breast cancer and bone metastases: a nationwide population-based cohort study in Denmark. Clin Epidemiol. 2013, 5: 97-103.","journal-title":"Clin Epidemiol"},{"key":"357_CR4","first-page":"701","volume":"88","author":"M Tubiana-hulin","year":"2001","unstructured":"Tubiana-hulin M, Beuzeboc P, Mauriac L, Barbet N, Frenay M, Monnier A, Pion JM, Switsers O, Misset JL, Assadourian S, Bessa E: Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer. 2001, 88: 701-707.","journal-title":"Bull Cancer"},{"key":"357_CR5","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","volume":"29","author":"V p CH","year":"2011","unstructured":"CH V p, Temin S, Yee GC, Janjan N, Barlow WE, Biermann JS, Bosserman LD, Geoghegan C, Hillner BE, Theriault RL, Zuckerman DS, JH V r: American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol. 2011, 29: 1221-1227. 10.1200\/JCO.2010.32.5209.","journal-title":"J Clin Oncol"},{"key":"357_CR6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/CIA.S2134","volume":"3","author":"O Bock","year":"2008","unstructured":"Bock O, Felsenberg D: Bisphosphonates in the management of postmenopausal osteoporosis\u2013optimizing efficacy in clinical practice. Clin Interv Aging. 2008, 3: 279-297.","journal-title":"Clin Interv Aging"},{"key":"357_CR7","doi-asserted-by":"publisher","first-page":"4739","DOI":"10.1200\/JCO.2008.16.4707","volume":"26","author":"DL Hershman","year":"2008","unstructured":"Hershman DL, Mcmahon DJ, Crew KD, Cremers S, Irani D, Cucchiara G, Brafman L, Shane E: Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2008, 26: 4739-4745. 10.1200\/JCO.2008.16.4707.","journal-title":"J Clin Oncol"},{"key":"357_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10549-010-1201-8","volume":"125","author":"JE Kim","year":"2011","unstructured":"Kim JE, Ahn JH, Jung KH, Kim SB, Kim HJ, Lee KS, Ro JS, Park YH, Ahn JS, Im YH, Im SA, Lee MH, Kim SY: Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01). Breast Cancer Res Treat. 2011, 125: 99-106. 10.1007\/s10549-010-1201-8.","journal-title":"Breast Cancer Res Treat"},{"key":"357_CR9","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ejca.2010.11.024","volume":"47","author":"CL Shapiro","year":"2011","unstructured":"Shapiro CL, Halabi S, Hars V, Archer L, Weckstein D, Kirshner J, Sikov W, Winer E, Burstein HJ, Hudis C, Isaacs C, Schilsky R, Paskett E: Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer. 2011, 47: 683-689. 10.1016\/j.ejca.2010.11.024.","journal-title":"Eur J Cancer"},{"key":"357_CR10","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","volume":"9","author":"M Gnant","year":"2008","unstructured":"Gnant M, Mlineritsch B, Luschin-ebengreuth G, Kainberger F, K\u00e4ssmann H, Piswanger-s\u00f6lkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlb\u00f6ck M, Jakesz R: Austrian Breast and Colorectal Cancer Study Group, Coleman RM. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008, 9: 840-849. 10.1016\/S1470-2045(08)70204-3.","journal-title":"Lancet Oncol"},{"key":"357_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1634\/theoncologist.9-90004-3","volume":"9","author":"JR Green","year":"2004","unstructured":"Green JR: Bisphosphonates: preclinical review. Oncologist. 2004, 9: 3-13.","journal-title":"Oncologist"},{"key":"357_CR12","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1038\/sj.bjc.6600925","volume":"88","author":"C Denoyelle","year":"2003","unstructured":"Denoyelle C, Hong L, Vannier JP, Soria J, Soria C: New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer. 2003, 88: 1631-1640. 10.1038\/sj.bjc.6600925.","journal-title":"Br J Cancer"},{"key":"357_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/ncponc0520","volume":"3","author":"D Santini","year":"2006","unstructured":"Santini D, Caraglia M, Vincenzi B, Holen I, Scarpa S, Budillon A, Tonini G: Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates. Nat Clin Pract Oncol. 2006, 3: 325-338. 10.1038\/ncponc0520.","journal-title":"Nat Clin Pract Oncol"},{"key":"357_CR14","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","volume":"365","author":"RE Coleman","year":"2011","unstructured":"Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Peterson J, Davies C, Hiley V, Gregory W, Bell R, Azure I, Van der vliet HM: Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011, 365: 1396-1405. 10.1056\/NEJMoa1105195.","journal-title":"N Engl J Med"},{"key":"357_CR15","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","volume":"12","author":"M Gnant","year":"2011","unstructured":"Gnant M, Mlineritsch B, Stoeger H, Luschin-ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G, Bauernhofer T, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Hochreiner G, Forsthuber EP, Fesl C, Greil R, Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria: Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011, 12: 631-641. 10.1016\/S1470-2045(11)70122-X.","journal-title":"Lancet Oncol"},{"key":"357_CR16","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/annonc\/mds277","volume":"24","author":"R Coleman","year":"2013","unstructured":"Coleman R, De Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, Von Minckwitz G, Sleeboom HP, Forbes J, Barrios C, Frassoldati A, Campbell I, Paija O, Martin N, Modi A, Bundred N: Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013, 24: 398-405. 10.1093\/annonc\/mds277.","journal-title":"Ann Oncol"},{"key":"357_CR17","first-page":"1192","volume":"118","author":"AM Brufsky","year":"2012","unstructured":"Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, Jin L, Warsi G, Argonza-aviles E, Hohneker J, Ericson SG, Perez EA: Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast Cancer patients receiving letrozole. Adv Cancer Res. 2012, 118: 1192-1201.","journal-title":"Adv Cancer Res"},{"key":"357_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/bjc.2012.210","volume":"107","author":"RL Aft","year":"2012","unstructured":"Aft RL, Naughton M, Trinkaus K, Weilbaecher K: Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II\/III breast cancer. Br J Cancer. 2012, 107: 7-11. 10.1038\/bjc.2012.210.","journal-title":"Br J Cancer"},{"key":"357_CR19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3816\/CBC.2010.n.062","volume":"10","author":"T Leal","year":"2010","unstructured":"Leal T, Tevaarwerk A, Love R, Stewart J, Binkley N, Eickhoff J, Parrot B, Mulkerin D: Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast Cancer. Clin Breast Cancer. 2010, 10: 471-476. 10.3816\/CBC.2010.n.062.","journal-title":"Clin Breast Cancer"},{"key":"357_CR20","volume-title":"Effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow up. Breast Cancer Symposium","author":"A Llombart","year":"2009","unstructured":"Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, Deleu I, Miller J, Schenk N, Neven P: Effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow up. Breast Cancer Symposium. 2009, abstract n.213 http:\/\/meetinglibrary.asco.org\/content\/40178-70"},{"key":"357_CR21","volume-title":"Fukunaga Masao. Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 36-month results. ASCO Annual Meeting","author":"S Takahashi","year":"2013","unstructured":"Takahashi S, Iwase T, Kohno N, Ishikawa T, Seung JK, Hosoda M, Horiguchi J, Yamauchi H, Hozumi Y, Okada M: Fukunaga Masao. Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 36-month results. ASCO Annual Meeting. 2013, abstract n.e20510 http:\/\/meetinglibrary.asco.org\/content\/110904-132"},{"key":"357_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.clbc.2011.08.002","volume":"12","author":"A Llombart","year":"2012","unstructured":"Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, Deleu I, Miller J, Schenk N, Neven P: Immediate administration of zoledronic acid reduces aromatase Inhibitor-Associated bone loss in postmenopausal women with early breast Cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer. 2012, 12: 40-48. 10.1016\/j.clbc.2011.08.002.","journal-title":"Clin Breast Cancer"},{"key":"357_CR23","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s10549-012-1973-0","volume":"133","author":"S Takahashi","year":"2012","unstructured":"Takahashi S, Iwase T, Kohno N, Ishikawa T, Taguchi T, Takahashi M, Horiguchi J, Nakamura S, Hozumi Y, Fukunaga M, Noguchi S: Efficacy of zoledronic acid in postmenopausal Japanese women with early breast Cancer receiving adjuvant letrozole: 12-month results. Breast Cancer Res Treat. 2012, 133: 685-693. 10.1007\/s10549-012-1973-0.","journal-title":"Breast Cancer Res Treat"},{"key":"357_CR24","first-page":"00081","volume":"959","author":"J Zhu","year":"2013","unstructured":"Zhu J, Zheng Y, Zhou Z: Oral adjuvant clodronate therapy could improve overall survival in early breast Cancer: Results from an updated systematic review and meta-analysis. Eur J Cancer. 2013, 959: 00081-00084.","journal-title":"Eur J Cancer"},{"key":"357_CR25","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1093\/annonc\/mdr612","volume":"23","author":"EF Solomayer","year":"2012","unstructured":"Solomayer EF, Gebauer G, Hirnle P, Janni W, L\u00fcck HJ, Becker S, Huober J, Kr\u00e4mer B, Wackwitz B, Wallwiener D, Fehm T: Influence of zoledronic acid on disseminated tumor cells in primary breast Cancer patients. Ann Oncol. 2012, 23: 2271-2277. 10.1093\/annonc\/mdr612.","journal-title":"Ann Oncol"},{"key":"357_CR26","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S1470-2045(10)70054-1","volume":"11","author":"R Aft","year":"2010","unstructured":"Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-macgregor M, Zhai J, Kuo S, Shannon W, Diemer K, Herrmann V, Dietz J, Ali A, Ellis M, Weiss P, Eberlein T, Ma C, Fracasso PM, Zoberi I, Taylor M, Gillanders W, Pluard T, Mortimer J, Weilbaecher K: Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast Cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 2010, 11: 421-428. 10.1016\/S1470-2045(10)70054-1.","journal-title":"Lancet Oncol"},{"key":"357_CR27","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1182\/blood-2003-05-1655","volume":"102","author":"F Dieli","year":"2003","unstructured":"Dieli F, Gebbia N, Poccia F, Caccamo N, Montesano C, Fulfaro F, Arcara C, Valerio MR, Meraviglia S, Di Sano C, Sireci G, Salerno A: Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in Cancer patients in vivo. Blood. 2003, 102: 2310-2311. 10.1182\/blood-2003-05-1655.","journal-title":"Blood"},{"key":"357_CR28","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-03-0325","volume":"10","author":"T Hiraga","year":"2004","unstructured":"Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T: Zoledronic acid inhibits visceral metastases in the 4T1\/luc mouse breast cancer model. Clin Cancer Res. 2004, 10: 4559-4567. 10.1158\/1078-0432.CCR-03-0325.","journal-title":"Clin Cancer Res"},{"key":"357_CR29","unstructured":"Gralow J, Livingston R: AD(2013),Phase III Randomized Study of Adjuvant Zoledronate versus Clodronate versus Ibandronate in Women With Resected Primary Stage I-III Adenocarcinoma of the Breast (SWOG-S0307). Curr Contr Trials.http:\/\/www.cancer.gov\/clinicaltrials\/featured\/trials\/swog-s0307,"},{"key":"357_CR30","volume-title":"Simultaneous Study of Docetaxel-Gemcitabine Combination adjuvant treatment, as well as Extended Bisphosphonate and Surveillance-Trial (SUCCESS)","author":"B Rack","year":"2010","unstructured":"Rack B, Schindlbeck C, Andergassen U, Lorenz R, Zwingers T, Schneeweiss A, Lichtenegger W, Beckmann MW, Sommer H, Pantel K, Friese K, Janni W: Simultaneous Study of Docetaxel-Gemcitabine Combination adjuvant treatment, as well as Extended Bisphosphonate and Surveillance-Trial (SUCCESS). 2010, San Antonio Breast Cancer Symposium \u2013 Cancer Therapy and Research Center at UT Health Schience Center, 8-12 December"},{"key":"357_CR31","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S1470-2045(12)70226-7","volume":"13","author":"AH Paterson","year":"2012","unstructured":"Paterson AH, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, Weir LM, Brufsky AM, Dakhil S, Lad T, Baez-diaz L, Gralow JR, Robidoux A, Perez EA, Zheng P, Geyer CE, Swain SM, Costantino JP, Mamounas EP, Wolmark N: Oral clodronate for adjuvant treatment of operable breast Cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol. 2012, 13: 734-742. 10.1016\/S1470-2045(12)70226-7.","journal-title":"Lancet Oncol"},{"key":"357_CR32","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ejca.2011.10.021","volume":"48","author":"T Yan","year":"2012","unstructured":"Yan T, Yin W, Zhou Q, Zhou L, Jiang Y, Du Y, Shao Z, Lu J: The efficacy of zoledronic acid in breast Cancer adjuvant therapy: a meta-analysis of randomised controlled trials. Eur J Cancer. 2012, 48: 187-195.","journal-title":"Eur J Cancer"},{"key":"357_CR33","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1634\/theoncologist.2012-0261","volume":"18","author":"A Valachis","year":"2013","unstructured":"Valachis A, Polyzos NP, Coleman RE, Gnant M, Eidtmann H, Brufsky AM, Aft R, Tevaarwerk AJ, Swenson K, Lind P, Mauri D: Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist. 2013, 18: 353-361. 10.1634\/theoncologist.2012-0261.","journal-title":"Oncologist"},{"key":"357_CR34","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med. 2002, 21: 1539-1558. 10.1002\/sim.1186.","journal-title":"Stat Med"},{"key":"357_CR35","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2307\/3001666","volume":"10","author":"WG Cochran","year":"1954","unstructured":"Cochran WG: The combination of estimates from different experiments. Biometrics. 1954, 10: 101-129. 10.2307\/3001666.","journal-title":"Biometrics"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-6-80.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T02:19:14Z","timestamp":1630549154000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/1756-8722-6-80"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,23]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["357"],"URL":"https:\/\/doi.org\/10.1186\/1756-8722-6-80","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,23]]},"assertion":[{"value":"23 July 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"80"}}